NeoGenomics to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference
Business Wire (Tue, 1-Sep 7:05 AM ET)
NeoGenomics Receives Medicare Coverage for RaDaR ST for Immunotherapy Treatment Response Monitoring
Business Wire (Wed, 26-Aug 4:17 PM ET)
NeoGenomics Reports Second Quarter 2026 Results
Business Wire (Tue, 28-Jul 4:05 PM ET)
NeoGenomics Announces Settlement of Voluntary Disclosure to OIG-HHS
Business Wire (Mon, 20-Jul 5:23 PM ET)
NeoGenomics Launches FDA-Approved PTEN IHC Companion Diagnostic for Prostate Cancer
Business Wire (Thu, 9-Jul 7:05 AM ET)
NeoGenomics to Report Second Quarter 2026 Financial Results on July 28, 2026
Business Wire (Tue, 7-Jul 7:05 AM ET)
NeoGenomics Appoints Carolyn Starrett to its Board of Directors
Business Wire (Thu, 25-Jun 7:05 AM ET)
NeoGenomics Announces Pricing of Offering of $275 Million Convertible Senior Notes
Business Wire (Wed, 17-Jun 6:00 AM ET)
NeoGenomics Announces Proposed Offering of $275 Million Convertible Senior Notes
Business Wire (Mon, 15-Jun 5:24 PM ET)
NeoGenomics Lifts Revenue Guidance After Double-Digit Growth and Profitable Quarter
Market Chameleon (Wed, 29-Apr 3:06 AM ET)
NeoGenomics Inc provides oncology diagnostic testing and consultative services which include technical laboratory services and professional interpretation of laboratory test results by licensed physicians or molecular experts in pathology and oncology. The company operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. The company operates in a single segment and derives revenue from clients by providing clinical cancer testing, interpretation, and consultative services, molecular and NGS testing, comprehensive technical and professional services offerings, clinical trials and research, validation laboratory services, and oncology data solutions.
Neogenomics trades on the NASDAQ stock market under the symbol NEO.
As of September 8, 2026, NEO stock price climbed to $17.67 with 380,089 million shares trading.
NEO has a beta of 0.89, meaning it tends to be less sensitive to market movements. NEO has a correlation of 0.04 to the broad based SPY ETF.
NEO has a market cap of $2.27 billion. This is considered a Mid Cap stock.
Last quarter Neogenomics reported $202 million in Revenue and $.05 earnings per share. This beat revenue expectation by $5 million and exceeded earnings estimates by $.04.
In the last 3 years, NEO traded as high as $21.22 and as low as $4.72.
The top ETF exchange traded funds that NEO belongs to (by Net Assets): IJR, FBT, VTI, IWM, VB.
NEO has outperformed the market in the last year with a price return of +119.2% while the SPY ETF gained +19.4%. NEO has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +56.2% and +4.1%, respectively, while the SPY returned +1.6% and +0.2%, respectively.
NEO support price is $16.85 and resistance is $17.92 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NEO shares will trade within this expected range on the day.